Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 4/20 | 0.53 |
| ▸ | MGLL | Q99685 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | THRA | P10827 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.50 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL787576 | 0.99 | MAPT (0.59) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL4376688 | 0.96 | MAPT (0.59) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL5767014 | 0.94 | MAPT (0.64) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL30506582 | 0.93 | MAPT (0.59) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL25293543 | 0.93 | MAPT (0.59) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL2591943 | 0.91 | MAPT (0.60) | MAPTPRSS1MGLLTSHRKMT2A | |
| SCHEMBL14705177 | 0.90 | MAPT (0.59) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL2149738 | 0.90 | MAPT (0.66) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL9307505 | 0.89 | SMPD1 (0.67) | MAPTPRSS1SMPD1MGLLTSHR | |
| SCHEMBL14930509 | 0.89 | SMPD1 (0.67) | MAPTPRSS1SMPD1MGLLTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017205661-A1 | METHOD OF TREATING CANCER BY TARGETING MYELOID-DERIVED SUPPRESSOR CELLS | PURDUE RESEARCH FOUNDATION (US) | 2017-11-30 | — | — | WO | disclosed |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | PURDUE RESEARCH FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | PURDUE RESEARCH FOUNDATION | 2017-09-21 | — | — | US | disclosed |
| WO-2016148674-A1 | CONJUGATES FOR TREATING DISEASES | ENDOCYTE, INC. (US) | 2016-09-22 | — | — | WO | disclosed |
| WO-2016085967-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | ENDOCYTE, INC. (US) | 2016-06-02 | — | — | WO | disclosed |
| EP-1981889-B1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI SA (FR) | 2014-01-15 | — | — | EP | disclosed |
| US-8163736-B2 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI-AVENTIS (FR) | 2012-04-24 | — | — | US | disclosed |
| EP-2386559-A1 | Cytotoxiv agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-11-16 | — | — | EP | disclosed |
| US-20110254808-A1 | REFLECTIVE TOUCH DISPLAY PANEL AND MANUFACTURING METHOD THEREOF | AU OPTRONICS CORPORATION (TW) | 2011-10-20 | — | — | US | disclosed |
| EP-2371827-A1 | Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use | SANOFI (FR) | 2011-10-05 | — | — | EP | disclosed |
| EP-1813614-B1 | Cytotoxic agents comprising new tomaymycin derivatives | SANOFI SA (FR) | 2011-10-05 | — | — | EP | disclosed |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
| EP-1981889-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007085930-A1 | CYTOTOXIC AGENTS COMPRISING NEW TOMAYMYCIN DERIVATIVES AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | WO | disclosed |
| EP-1813614-A1 | Cytotoxic agents comprising new tomaymycin derivatives | Sanofi-Aventis (FR) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266303-A1 | METHODS OF TREATING CANCER BY TARGETING TUMOR-ASSOCIATED MACROPHAGES | FOLR1, FOLR2, FOLH1 | MAPT 3663/4885PRSS1 2636/4885SMPD1 1281/4885 |
| US-20090036431-A1 | Cytotoxic Agents Comprising New Tomaymycin Derivatives | TOMM70, TOMM34, TOMM40 | MAPT 3729/4885PRSS1 1709/4885SMPD1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.